# 2026-05623: FDA Invites Feedback on Advisory Committee Info Forms

2026-05623, Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Advisory Committees, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-23, effective Either electronic or written comments on the collection of information must be submitted by May 22, 2026. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05623
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05623
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Advisory Committees
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 13852
- Published: 2026-03-23
- Effective: Either electronic or written comments on the collection of information must be submitted by May 22, 2026.
- Comments close: 2026-05-22
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Invites Feedback on Advisory Committee Info Forms

## Summary

The FDA wants your thoughts on how it collects info from its advisory committees. This is about keeping paperwork clear and easy, with no big changes or costs expected. If you have ideas, send them in by May 22, 2026, to help shape how the FDA works with experts.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with certain FDA advisory committee activities.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05623 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/23/2026-05623/agency-information-collection-activities-proposed-collection-comment-request-food-and-drug)
- [2026-05623 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05623.pdf)

## Related
- [Previous: 2026-05622, Application for Renewal of Authorization To Export Electric Energy; Rainbow Ene…](https://policyrisk.com/federal-register/2026-05622)
- [Next: 2026-05624, Rio Grande LNG, LLC, Rio Grande LNG Train 4, LLC, & Rio Grande LNG Train 5, LLC…](https://policyrisk.com/federal-register/2026-05624)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05623 (as of 2026-06-08).
